Financhill
Sell
16

HUM Quote, Financials, Valuation and Earnings

Last price:
$184.10
Seasonality move :
-1.92%
Day range:
$178.42 - $184.50
52-week range:
$169.61 - $315.35
Dividend yield:
1.92%
P/E ratio:
18.77x
P/S ratio:
0.17x
P/B ratio:
1.25x
Volume:
2.7M
Avg. volume:
2.4M
1-year change:
-27.2%
Market cap:
$22.1B
Revenue:
$129.7B
EPS (TTM):
$9.81

Analysts' Opinion

  • Consensus Rating
    Humana, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 6 Buy ratings, 17 Hold ratings, and 2 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $231.57, Humana, Inc. has an estimated upside of 25.78% from its current price of $184.10.
  • Price Target Downside
    According to analysts, the lowest downside price target is $146.00 representing 20.7% downside risk from its current price of $184.10.

Fair Value

  • According to the consensus of 25 analysts, Humana, Inc. has 25.78% upside to fair value with a price target of $231.57 per share.

HUM vs. S&P 500

  • Over the past 5 trading days, Humana, Inc. has underperformed the S&P 500 by -3.69% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Humana, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Humana, Inc. has grown year-over-year revenues for 33 quarters straight. In the most recent quarter Humana, Inc. reported revenues of $32.5B.

Earnings Growth

  • Humana, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Humana, Inc. reported earnings per share of -$6.61.
Enterprise value:
34.6B
EV / Invested capital:
1.15x
Price / LTM sales:
0.17x
EV / EBIT:
22.25x
EV / Revenue:
0.27x
PEG ratio (5yr expected):
--
EV / Free cash flow:
223.17x
Price / Operating cash flow:
143.32x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
2.44%
Net Income Margin (TTM):
0.93%
Return On Equity:
6.77%
Return On Invested Capital:
3.96%
Operating Margin:
-2.49%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-31 2024-12-31 2025-12-31 2024-12-31 2025-12-31
Income Statement
Revenue $106.4B $117.8B $129.7B $29.2B $32.5B
Gross Profit -- -- -- -- --
Operating Income $4.1B $2.6B $2.7B -$543M -$808M
EBITDA -- -- -- -- --
Diluted EPS $19.83 $9.96 $9.81 -$5.75 -$6.61
Period Ending 2021-12-31 2022-12-31 2023-12-31 2024-12-31 2025-12-31
Balance Sheet
Current Assets $24.9B $26.2B $30B $29.8B $32.7B
Total Assets $44.7B $43.7B $46.9B $46.3B $48.9B
Current Liabilities $15.3B $17.2B $18.9B $16.9B $16.3B
Total Liabilities $28.6B $28.4B $30.6B $29.9B $31.2B
Total Equity $16.1B $15.4B $16.3B $16.4B $17.7B
Total Debt $11.3B $9.7B $10.8B $11.7B $12.4B
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-31 2024-12-31 2025-12-31 2024-12-31 2025-12-31
Cash Flow Statement
Cash Flow Operations $4B $3B $921M -$528M -$1.7B
Cash From Investing -$3.5B -$3B $2.3B -$63M $632M
Cash From Financing -$856M -$2.5B -$1.2B -$2.3B -$168M
Free Cash Flow $3B $2.4B $155M -$682M -$2.1B
HUM
Sector
Market Cap
$22.1B
$24M
Price % of 52-Week High
58.38%
48.29%
Dividend Yield
1.92%
0%
Shareholder Yield
2.3%
-1.62%
1-Year Price Total Return
-27.2%
-22.92%
Beta (5-Year)
0.437
0.500
Dividend yield:
1.92%
Annualized payout:
$3.54
Payout ratio:
54.8%
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $186.09
200-day SMA
Sell
Level $253.47
Bollinger Bands (100)
Sell
Level 222.8 - 284.26
Chaikin Money Flow
Buy
Level 297.6M
20-day SMA
Sell
Level $213.55
Relative Strength Index (RSI14)
Sell
Level 28.60
ADX Line
Sell
Level 45.4
Williams %R
Neutral
Level -72.8661
50-day SMA
Sell
Level $244.30
MACD (12, 26)
Sell
Level -21.03
25-day Aroon Oscillator
Sell
Level -72
On Balance Volume
Neutral
Level 115.2M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (4.5833)
Buy
CA Score (Annual)
Level (0.0985)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-0.738)
Buy
Piotroski F Score (Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (7)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Stock Forecast FAQ

In the current month, HUM has received 6 Buy ratings 17 Hold ratings, and 2 Sell ratings. The HUM average analyst price target in the past 3 months is $231.57.

  • Where Will Humana, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Humana, Inc. share price will rise to $231.57 per share over the next 12 months.

  • What Do Analysts Say About Humana, Inc.?

    Analysts are divided on their view about Humana, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Humana, Inc. is a Sell and believe this share price will drop from its current level to $146.00.

  • What Is Humana, Inc.'s Price Target?

    The price target for Humana, Inc. over the next 1-year time period is forecast to be $231.57 according to 25 Wall Street analysts, 6 of them rate the stock a Buy, 2 rate the stock a Sell, and 17 analysts rate the stock a Hold.

  • Is HUM A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Humana, Inc. is a Hold. 17 of 25 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of HUM?

    You can purchase shares of Humana, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Humana, Inc. shares.

  • What Is The Humana, Inc. Share Price Today?

    Humana, Inc. was last trading at $184.10 per share. This represents the most recent stock quote for Humana, Inc.. Yesterday, Humana, Inc. closed at $184.10 per share.

  • How To Buy Humana, Inc. Stock Online?

    In order to purchase Humana, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will UnitedHealth Stock Recover?
Will UnitedHealth Stock Recover?

Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…

Is Lumentum The Best Laser Stock to Buy?
Is Lumentum The Best Laser Stock to Buy?

Though certainly less well-known than the huge tech businesses that…

Is Planet Fitness Stock Undervalued?
Is Planet Fitness Stock Undervalued?

Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…

Stock Ideas

Buy
51
Is NVDA Stock a Buy?

Market Cap: $4.4T
P/E Ratio: 62x

Sell
43
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 34x

Sell
44
Is GOOG Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 28x

Alerts

Buy
77
CPS alert for Feb 14

Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.

Buy
58
TPH alert for Feb 14

Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.

Sell
20
IRON alert for Feb 14

Disc Medicine, Inc. [IRON] is down 21.88% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock